Zosano Pharma Corporation (ZSAN)

Trade ZSAN now with
7/20/2021 8:36:17 AM Zosano Pharma Announces Issuance Of U.S. Patent For Method Of Achieving Therapeutic Levels With M207 For Migraine
2/22/2021 8:43:42 AM Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes From FDA
2/1/2021 8:10:22 AM Zosano Pharma Reports NDA Resubmission Plans Following Type A Meeting With FDA
10/21/2020 8:32:29 AM Zosano Receives Complete Response Letter From FDA For Qtrypta
6/13/2020 9:21:43 AM Zosano Pharma Presents New Post-hoc Efficacy Analyses Of Qtrypta For The Acute Treatment Of Migraine
3/5/2020 8:17:04 AM Zosano Pharma Plans 11 Mln Direct Offering